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Among breast cancers, triple-negative breast cancer
(TNBC) is the most poorly understood and is refrac-
tory to current targeted therapies. Using a genetic
screen,we identify thePTPN12 tyrosinephosphatase
as a tumor suppressor in TNBC. PTPN12 potently
suppresses mammary epithelial cell proliferation
and transformation. PTPN12 is frequently compro-
mised in human TNBCs, and we identify an upstream
tumor-suppressor network that posttranscriptionally
controls PTPN12. PTPN12 suppresses transforma-
tion by interacting with and inhibiting multiple onco-
genic tyrosine kinases, including HER2 and EGFR.
The tumorigenic andmetastatic potential of PTPN12-
deficient TNBC cells is severely impaired upon resto-
ration of PTPN12 function or combined inhibition of
PTPN12-regulated tyrosine kinases, suggesting that
TNBCs are dependent on the proto-oncogenic tyro-
sine kinases constrained by PTPN12. Collectively,
these data identify PTPN12 as a commonly inacti-
vated tumor suppressor and provide a rationale for
combinatorially targeting proto-oncogenic tyrosinekinases in TNBC and other cancers based on their
profile of tyrosine-phosphatase activity.INTRODUCTION
Breast cancer is the most common malignancy among women
and is comprised of a heterogeneous group of diseases stratified
into three major subtypes (Di Cosimo and Baselga, 2010; Jemal
et al., 2008). Two of these are defined by expression of steroid
hormone receptors (estrogen receptor [ER] and progesterone
receptor [PR]) or amplification/overexpression of the receptor
tyrosine kinase (RTK) HER2. Agents targeting these proteins
have led to significant increases in patient survival (Osborne,
1998; Slamon et al., 1989). In contrast, the triple-negative breast
cancer (TNBC) subtype is defined only by the absence of ER
and PR expression or HER2 amplification, underscoring our
lack of understanding of key pathways driving TNBC. TNBC
comprises approximately 20% of breast cancer, and the prog-
nosis for patients with TNBC is poor because of its propensity
for recurrence and metastasis and a lack of effective targeted
therapeutics (Hurvitz and Finn, 2009). Consequently, a major
challenge remaining in breast cancer treatment is to identify
aberrant signaling networks underlying this aggressive subtype
of breast cancer.Cell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc. 703
Protein tyrosine phosphorylation plays a central role in
cellular physiology and in cancer (Hunter, 2009). For instance,
aberrant activation of the human epidermal growth factor
receptor (HER) family of RTKs occurs frequently in many malig-
nancies, including breast, lung, and brain cancer (Yarden and
Sliwkowski, 2001). Although HER2 signaling is required for tumor
maintenance in HER2-amplified disease (Slamon et al., 1989),
the role of HER2 and other HER family tyrosine kinases (TKs) in
breast cancer subtypes lacking HER2 amplification is unclear.
Notably, in the absence of TK mutational activation or amplifica-
tion, other pathways that regulate HER2 and other TKs may also
be involved in tumorigenesis but remain to be elucidated.
Protein tyrosine phosphatases (PTPs) also regulate the equi-
librium of tyrosine phosphorylation and, in principle, can serve
as antagonists to TK signaling to play a prominent role in tumor
suppression (Tonks, 2006). However, much less is known about
the role of PTPs in suppressing tumorigenesis. In this study
we have employed an unbiased functional screen for tumor
suppressors and identified a role for the tyrosine phosphatase
PTPN12 in TNBC. Loss of PTPN12 leads to malignant transfor-
mation of human mammary epithelial cells (HMECs) through
multi-TK activation. PTPN12 function is frequently compromised
in TNBC by deletions, defective sequence variants, or loss of ex-
pression, suggesting that HER2/EGFR and other RTK signaling
is aberrantly activated in non-HER2-amplified breast cancers.
Restoring PTPN12 expression in PTPN12-deficient TNBC cells
inhibits their proliferation, tumorigenicity, and metastatic poten-
tial in vivo. These results identify PTPN12 as a tumor suppressor
and suggest that combinatorial TK signaling is a key dependency
in TNBC and, therefore, a target for cancer therapies.
RESULTS
PTPN12 Suppresses Transformation of HMECs
Signal transduction networks play key roles in the malignant
behavior of cancer cells. To identify new networks that regulate
cellular transformation in human breast cancer, we performed
a genetic screen for kinases and phosphatases that suppress
cellular transformation in genetically engineered HMECs (Fig-
ure 1A). HMECs isolated from healthy human breast tissue were
transduced with lentiviruses expressing hTERT and SV40-
Large T. These cells (herein termed TLM-HMECs) are immortal
but do not proliferate in the absence of extracellular matrix
(ECM) (Westbrook et al., 2005). For the screen we generated a
shRNA library targeting all human kinases and phosphatases
(six shRNAs/gene). TLM-HMECs were transduced with the
shRNA library and assessed for cellular transformation by cultur-
ing in the absence of ECM.We isolated 530 anchorage-indepen-
dent colonies from two independent screens and identified
proviral shRNAsbysequencing.Genes identified inboth replicate
screens were considered candidate suppressors of transforma-
tion. Several genes were targeted by multiple independent
shRNAs, including the well-documented tumor suppressors
PTEN and LKB1 (Hemminki et al., 1998; Li et al., 1997).
The top-scoring candidate from this genetic screen was the
PTP PTPN12 (aka PTP-PEST) (Yang et al., 1993). Many TKs
have been shown to be important drivers of human cancer, but
PTPs that antagonize proto-oncogenic TKs have not received704 Cell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc.equal attention. Notably, PTPN12 has not been previously
implicated in tumor suppression. Three independent PTPN12
shRNAs exhibited robust cellular transformation in TLM-HMECs
(Figure 1C), and the degree of depletion correlated with the
severity of the phenotype (Figures 1B and 1C). In addition,
restoring PTPN12 expression with an exogenous PTPN12
cDNA completely suppressed transformation (Figure 1D), ruling
out RNAi off-target effects. Collectively, these data indicate that
PTPN12 is a potent suppressor of transformation in mammary
epithelial cells.
Loss of PTPN12 Disrupts Proper 3D Acinar Formation
of Mammary Epithelial Cells
Proper control of cell proliferation, survival, and polarity in the
mammary epithelium is critical for normal mammary gland func-
tion, and dysregulation of these processes is considered to be
a driver in breast cancer initiation and progression (Bissell
et al., 2002). To determine whether PTPN12 regulates these
processes during acini formation, we tested the effects of
PTPN12 loss of function in 3D culture of MCF10A cells, a nontu-
morigenic mammary epithelial cell line. When cultured in
semisolid ECM, these cells form a polarized acinar structure
that resembles mammary acini in vivo (Petersen et al., 1992).
MCF10A cells transduced with control- or PTPN12-shRNAs
were analyzed for PTPN12 expression and formation of
3D acini (Figure 1E, and see Figure S1E available online).
PTPN12 depletion significantly disrupted normal acini formation,
with >85% forming aberrant structures (Figure 1E). Confocal
microscopy revealed that PTPN12 loss of function significantly
increased ectopic proliferation (Figures S1B and S1C) but did
not lead to a compensatory increase in apoptosis (data not
shown) like other oncogenic insults (Debnath et al., 2002),
consistent with the significantly expanded cellularity and filled
lumen in acini upon PTPN12 depletion. These observations
suggest that PTPN12 is required to establish proper proliferative
arrest during acinar formation.
To determine whether PTPN12 is required to maintain prolifer-
ative arrest in preestablished acini, we utilized an inducible
shRNA vector that encodes a shRNA and tRFP on the same
inducible transcript (Figure S1D, top panel) (Meerbrey et al.,
2011). Addition of doxycycline (dox) results in tRFP fluorescence
and PTPN12 depletion within 72 hr (Figure S1E). MCF10A cells
encoding an inducible control- or PTPN12-shRNA were seeded
in 3D culture, and after acini formation (day 9), dox was added
to the culture medium, and acini morphology was assessed
at day 15. Addition of dox had no effect in cells expressing
control shRNA, but cells expressing PTPN12 shRNA exhibited
a significant increase in aberrant acini (Figure S1F). Thus,
PTPN12 is required to establish and maintain proliferative arrest
in mammary epithelial acini.
PTPN12 Phosphatase Activity Is Required to Suppress
Cellular Transformation
To determine the role of the PTPN12 phosphatase activity in
transformation, we mutated amino acid C231 to S, which is
known to ablate phosphatase activity (Garton et al., 1996). A
shRNA-resistant PTPN12-C231S cDNA was transduced into
TLM-HMECs expressing a PTPN12 shRNA. Unlike wild-type
control
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Figure 1. A Genetic Screen for Tumor Suppressors Identifies PTPN12
(A) Schematic of genetic screen for suppressors of HMEC transformation. A pool of retroviral shRNAs was transduced into TLM-HMECs in duplicate, and
assessed for anchorage-independent proliferation. shRNAs were PCR amplified and sequenced from macroscopic colonies.
(B) Depletion of PTPN12. PTPN12 protein expression in TLM-HMECs transduced with vectors expressing the indicated shRNAs with quantification below.
(C) PTPN12 loss of function transforms TLM-HMECs. Anchorage-independent proliferation in TLM-HMECs transduced with the indicated shRNAs.
(D) Restoring PTPN12 expression suppresses transformation by PTPN12 shRNA. Anchorage-independent proliferation in TLM-HMECs transduced with control
or PTPN12-shRNA in combination with PTPN12 cDNA as indicated.
(E) PTPN12 regulates acinar morphogenesis. MCF10A cells expressing the indicated shRNAs were analyzed for 3D acinar morphogenesis in vitro (day 15 after
seeding) and quantified for the number of aberrant mammary acini.
(F) The enzymatic activity of PTPN12 is required for transformation suppression. TLM-HMECs expressing a PTPN12 shRNA were transduced with lentivirus-
encoding control or shRNA-resistant PTPN12-C231S mutant cDNA and assessed for PTPN12 expression by western (top) and anchorage-independent
proliferation (bottom).
Error bars represent standard error.
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PTPN12 (Figure 1D), the C231S mutant had no effect on HMEC
transformation (Figure 1F), suggesting that the tyrosine-phos-
phatase activity of PTPN12 is required for suppressing
transformation.
PTPN12 Regulates an EGFR/HER2-Centered RTK
Network in HMECs
To elucidate the role of the phosphatase activity of PTPN12 in
suppressing transformation, it is critical to identify the phosphor-
ylation events altered in response to PTPN12 loss. Thus, we
used a quantitative proteome-wide method that combines
anti-phosphotyrosine peptide immunoprecipitation, differential
peptide labeling, and LC-MS/MS-based phosphopeptide identi-
fication and quantitation (Hsu et al., 2003) to search for phospho-
tyrosine-peptides whose abundance increases when PTPN12 is
depleted. TLM-HMECs engineered with an inducible PTPN12-
shRNA were profiled with and without PTPN12 depletion. We
identified 99 phosphotyrosine peptides corresponding to 69
proteins whose tyrosine phosphorylation increased by greater
than 1.5-fold in the absence of PTPN12 (see Table S1). Many
of these proteins have been previously described to interact
with PTPN12, including the known substrate p130CAS (or
BCAR1). However, whereas p130CAS was highly phosphory-
lated, depletion experiments indicate it plays only a minor role
in cellular transformation due to PTPN12 loss (Figure S2), sug-
gesting that other signaling proteins may play more important
roles in the tumor-suppressive function of PTPN12.
Analysis of these PTPN12-regulated proteins using Ingenuity
and the Human Protein Reference Database (HPRD) resources
revealed two highly connected protein-protein interaction
networks. The number of interactions within this PTPN12-regu-
lated network was highly enriched (p < 0.001, Monte Carlo
procedure), consisting of 46% of all PTPN12-regulated proteins
identified (Figures 2A and 2B). The first network consists of
proteins and signaling pathways known to govern proliferation
and survival in human cancer, with the RTK EGFR being a central
component of both the literature-based Ingenuity network and
the protein interaction-based HPRD network (p < 0.001, Monte
Carlo procedure) (Figures 2A and 2B). The second network is
comprised of proteins controlling the actin cytoskeleton, consis-
tent with the role of PTPN12 in regulating cell motility and
possibly metastasis (Angers-Loustau et al., 1999) (Figures S2A
and S2B). Because EGFR and its related receptors play critical
roles in breast cancer initiation and progression (Brandt et al.,
2000; Muller et al., 1988; Slamon et al., 1989), we focused ourFigure 2. PTPN12 Interacts with and Inhibits the HER2/EGFR Signaling
(A and B) Tyrosine phosphoproteins regulated by PTPN12. HMECs expressing
PTPN12 for tyrosine-phosphorylated peptides using a quantitative proteomic ap
PTPN12-regulated phosphoproteins were analyzed via (A) Ingenuity and (B) the
(C) HER2 and EGFR RTKs interact with PTPN12 in HMECs. The left panel show
N terminus of YFP, and RTKs were fused with the C terminus of YFP. HMECs wer
C-YFP cDNAs. In the right panel the interaction between PTPN12 and HER fami
(D) Substrate-trapping PTPN12mutant displays increased interaction with HER2.
N-YFP in combination with HER2-C-YFP were analyzed for cellular fluorescence
(E) PTPN12 loss of function elicits hyperactivation of HER2, EGFR, and a MAPK-s
cultured ± dox for 3 days, starved of growth factors, and analyzed for levels of t
(F) PTPN12 suppresses HER2, EGFR, and MAPK signaling. HMECs engineered
Error bars represent standard error.attention on the potential regulatory interaction between
PTPN12 and the EGFR family of receptor TKs.
EGFR is one of four RTKs in the HER family, with HER2 playing
themost prominent role in human breast cancer. These RTKs are
known to promote cell survival and proliferation and signal via
autophosphorylation and recruitment of additional substrates
through recognition of these autophosphorylation sites (Yarden
and Sliwkowski, 2001). In principle, tyrosine phosphatases can
counter the activity of these RTKs by dephosphorylation of
RTK substrates or the RTKs themselves. To determine if
PTPN12 interacts with EGFR and other RTKs in HMECs, we em-
ployed a bimolecular fluorescence complementation (BiFC)
system (Giepmans et al., 2006; Kerppola, 2006). Each of the
HER family RTKs (EGFR, HER2, HER3, and HER4) was fused
on its C termini with the C-terminal half of YFP. These fusion
cDNAs were transduced into TLM-HMECs expressing PTPN12
fused to the N terminus of YFP. If an interaction occurs between
PTPN12 and the candidate RTK, this enables folding of the
N- and C-terminal fragments of YFP to produce a fluorescent
YFP protein (Figure 2C, left panel). EGFR and HER2 exhibited
strong interaction with PTPN12, as determined by cellular YFP
fluorescence (Figure 2C, right panel). In addition, HER2 interac-
tion was enhanced with the substrate-trapping C231S mutant
of PTPN12 (Figure 2D). These data suggest that PTPN12
may directly interact with and inhibit EGFR/HER2 signaling to
suppress transformation.
PTPN12 Inhibits an EGFR/HER2-MAPK Signaling Axis
to Suppress Cellular Transformation
HER2 and EGFR signal via homo- and heterodimerization and
subsequent phosphorylation of their C-terminal tails on sites
that serve as hubs for recruitment and activation of signaling
complexes (Yarden and Sliwkowski, 2001). To determine
whether PTPN12 controls EGFR and HER2, we assessed the
phosphorylation status of EGFR and HER2 in cells expressing
an inducible PTPN12 shRNA. Depletion of PTPN12 led to an
increase in HER2 (Y1248) and EGFR (Y1148) phosphorylation.
Consistent with our phosphoproteomic data, the Y1148 residue
of EGFR showed the strongest differential phosphorylation
(>2-fold) in response to PTPN12 depletion (Figure 2E). Recipro-
cally, inducible expression of a PTPN12 cDNA in TLM-HMECs
decreased HER2-pY1248 and EGFR-pY1148, but not other
phosphotyrosine residues on EGFR (Figure 2F; data not shown).
Thus, PTPN12 selectively regulates phosphorylation of a subset
of tyrosine residues on EGFR and HER2.Axis
an inducible PTPN12-shRNA were quantified in the presence and absence of
proach (described in Experimental Procedures). Interactions between the 69
HPRD.
s the experimental design of the BiFC system. PTPN12 was fused with the
e transduced with retroviruses expressing PTPN12-N-YFP and individual RTK-
ly RTKs was assessed by cellular fluorescence. Asterisk indicates p < 0.01.
Breast cancer cells expressing PTPN12-WT-N-YFP ormutant PTPN12-C231S-
.
ignaling cascade. HMECs engineered with an inducible PTPN12-shRNA were
he indicated total and phosphorylated proteins by western.
with an inducible PTPN12-cDNA were cultured and analyzed as in (E).
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We next evaluated the effects of PTPN12 suppression on
known EGFR/HER2 effector pathways (RAS/MAPK and PI3K/
AKT). PTPN12 depletion led to hyperactivation of ERK/RSK/S6
signaling but had no effect on phosphorylation of PI3K-effectors
AKT and S6K1 (Figure 2E). Likewise, ectopic expression of
PTPN12 decreased the phosphorylation of ERK/RSK/S6 but
not PI3K signaling (Figure 2F). This is consistent with previous
observations that pY1148 of EGFR serves as a binding site for
the adaptor protein SHC and mediates activation of RAS-
MAPK signaling (Batzer et al., 1995; Songyang et al., 1995).
Furthermore, SHC is phosphorylated upon EGFR recruitment,
and we found SHC1 phosphorylation on Y317 to be regulated
by PTPN12 (Table S1). Taken together, these results indicate
that loss of PTPN12 function leads to hyperphosphorylation of
HER2/EGFR and activation of downstreamRAS/MAPK signaling
in HMECs.
To determine whether HER2/EGFR is required for transforma-
tion, TLM-HMECs expressing a dox-inducible PTPN12-shRNA
were depleted of EGFR or HER2 (Figure 3A). Transformation
by the PTPN12 shRNAwas significantly impaired upon depletion
of EGFR or HER2 (Figure 3B). Depletion of the adaptor protein
SHC also reduced cellular transformation in response to a
PTPN12 shRNA (Figures 3C and 3D), consistent with the hypoth-
esis that PTPN12 suppresses transformation by inhibiting
a HER2/EGFR/SHC/MAPK signaling axis. Furthermore, pharma-
cologic inhibition of HER2 and EGFR or MEK strongly sup-
pressed transformation in cells depleted of PTPN12 (Figures
3E and 3F, respectively). Collectively, these data demonstrate
that PTPN12 suppresses cellular transformation in HMECs by
antagonizing HER2/EGFR phosphorylation and downstream
MAPK signaling.
PTPN12 Is Inactivated by Mutation in Human TNBC
The role of PTPN12 in transformation and control of proto-
oncogenic pathways led us to ask whether PTPN12 is inacti-
vated in breast cancer. Initially, we examined whether the
PTPN12 locus is deleted frequently in breast cancer by
analyzing a publicly available data set of 243 human primary
breast tumors and tumor-derived cell lines for which genomic
copy number has been assessed (Beroukhim et al., 2010).
Indeed, 22.6% of breast cancers exhibit evidence of deletion
(one homozygous deletion of 15.0 Mb) at the PTPN12
locus, though the deletions exhibit a median size of 22.9 Mb,
suggesting that multiple driver mutations may exist in this
region. PTPN12 deletion in lung cancer was also frequent
(13.8%) and typically encompassed large chromosomal regions
(median deletion size of 22.2 Mb; two homozygous deletions of
1.3 and 0.7 Mb). An analysis of focal deletions (<2.0 Mb) en-
compassing PTPN12 in these tumors revealed a minimum
common region (MCR) of only 0.61 Mb that spans five genes
(Figure S3). These data suggest that PTPN12 is inactivated, in
part, via deletion in a wide range of cancers and support the
hypothesis that PTPN12 is a frequently inactivated tumor
suppressor.
Because PTPN12 depletion leads to hyperactivation of HER2/
EGFR, PTPN12 inactivation may occur more frequently in non-
HER2-amplified human breast cancers. Therefore, to search
for potential tumorigenic sequence variants, we sequenced the708 Cell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc.coding exons of PTPN12 in 83 TNBCs and cell lines (75 primary
tumors and eight cell lines). Primary sequence analysis revealed
nonsynonymous sequence alterations in PTPN12 in 4.8% of
TNBCs (three primary tumors; one tumor-derived cell line) (Fig-
ure 4A). Three variants were heterozygous, one was homozy-
gous, and none was present in reference genomes or single-
nucleotide polymorphism (SNP) databases. These amino acid
changes (shown in Figure 4B) occurred in the highly conserved
catalytic cleft of PTPN12 (H230Y) and within close proximity to
a known protein-interaction domain (E690G and W699G) (Pao
et al., 2007). In contrast we found no evidence of sequence alter-
ations in 202 primary breast cancers from the other predominant
breast cancer subtypes (ER+ and HER2-amplified), suggesting
that PTPN12 may be inactivated more frequently in the TNBC
subtype (p < 0.001, Fisher’s exact test).
To determine whether these sequence variants affected
PTPN12 function, wild-type (WT) ormutant PTPN12 cDNAs lack-
ing the 30UTR were introduced into TLM-HMECs expressing
PTPN12 shRNA targeting the PTPN12 30UTR. All cDNAs
restored PTPN12 protein to endogenous levels (Figures 4C
and 4D, top panels). Similar to WT PTPN12, the R30Q mutant
suppressed PTPN12-shRNA induced transformation. In con-
trast, the three remaining tumor-derived mutants (H230Y,
E690G, and W699G) did not suppress transformation. In fact,
TLM-HMECs expressing these mutants formed 25%–50%
more colonies than cells with PTPN12 shRNA alone (Figures
4C and 4D, bottom panels), suggesting that these loss-of-func-
tion PTPN12 mutations are potentially dominant negative.
We further examined whether the defective H230Y variant per-
turbed PTPN12 function in an independent system (MCF10A
acinar formation). WT and H230Y mutant PTPN12 cDNAs were
transduced into MCF10A cells expressing control- or PTPN12-
shRNAs and were expressed at comparable levels (Figure S4).
In contrast to WT PTPN12, the H230Y mutant did not suppress
aberrant acini formation in the presence of PTPN12-shRNA
(Figures 4F and 4G). In addition the H230Y mutant elicited aber-
rant acini in the presence of endogenous PTPN12, again sug-
gesting dominant-negative activity. Although we were unable
to determine if these defective variants were somatic tumor
mutations due to the lack of patient-matched nontumor DNA,
our functional data indicate that these defective PTPN12 variants
are likely causal in TNBCs.
During sequencing of the PTPN12 locus, we observed a SNP
occurring more frequently in tumors (7.3%, n = 274) than in non-
disease control patients (2.5%, n = 1142) (p = 0.004) (Easton
et al., 2007). Notably, this SNP results in a threonine to alanine
change in PTPN12 (T573A). We have previously shown that
this threonine is phosphorylated in cells (Dephoure et al.,
2008), suggesting that this residue may have a regulatory func-
tion for PTPN12. Based on these observations, we tested the
hypothesis that the PTPN12-T573A allele may have reduced
ability to suppress transformation. Indeed, a PTPN12-T573A
cDNA did not completely suppress transformation in PTPN12-
depleted TLM-HMECs (Figure 4E) and conferred aberrant acinar
morphogenesis in 3D culture (Figure 4H). These results suggest
that the PTPN12 T573A SNP is a partial loss-of-function allele
with dominant-negative properties. Intriguingly, our analysis of
primary data from a genome-wide association study (GWAS) of
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Figure 3. PTPN12 Suppresses Transformation by Inhibiting HER2/EGFR Signaling
(A) EGFR and HER2 depletion in TLM-HMECs. TLM-HMECs expressing control, EGFR, or HER2-targeting shRNAs were analyzed by western blotting for EGFR,
HER2, and vinculin (loading control) as indicated.
(B) EGFR and HER2 RTKs are required for cellular transformation upon PTPN12 depletion. TLM-HMECs encoding an inducible PTPN12-shRNAwere transduced
with the indicated shRNAs and assessed for anchorage-independent proliferation ± dox.
(C) SHC depletion in HMECs. TLM-HMECs expressing control or SHC-targeting shRNAs were analyzed by western for SHC and vinculin as indicated.
(D) SHC is required for cellular transformation upon PTPN12 depletion. TLM-HMECs encoding an inducible PTPN12-shRNA were transduced with the indicated
shRNAs and assessed for anchorage-independent proliferation ± dox.
(E) HER2/EGFR inhibitors block PTPN12 depletion-induced transformation. TLM-HMECs expressing the indicated shRNAs were assessed for anchorage-
independent growth ± a HER2/EGFR inhibitor (lapatinib).
(F) Transformation by PTPN12 inactivation requires MAPK signaling. TLM-HMECs expressing the indicated shRNAs were assessed for anchorage-independent
proliferation ± a MEK inhibitor (U0126).
Error bars represent standard error.SNPs contributing to breast cancer (Easton et al., 2007) revealed
that the homozygous PTPN12-573A genotype occurred more
frequently in the germline of patients with breast cancer.
Although this observation did not reach statistical significance
(p = 0.2), the trend (combined with our functional studies) is
consistent with the allele conferring enhanced susceptibility to
breast cancer. This raises the possibility that a relatively frequent
allele of PTPN12 may confer a predisposition to breast cancer,a hypothesis that will need to be rigorously tested in further
experiments.
Loss of PTPN12 Expression Occurs More Frequently
in TNBC
Our results suggest that PTPN12 functions as a suppressor of
malignant transformation andmay be inactivated in TNBC.Given
the deletions and sequence alterations in PTPN12, we wishedCell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc. 709
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to test whether PTPN12 functionmay also be frequently compro-
mised by loss of expression. Unfortunately, PTPN12 mRNA
expression is high in stromal compartments, thus precluding
the use of RNA profiling to evaluate PTPN12 levels in public
breast cancer data sets. To circumvent this problem we devel-
oped a specific immunohistochemical assay for PTPN12 protein
(Figure S5A) and evaluated expression of PTPN12 in an indepen-
dent cohort of 185 breast cancers. PTPN12 protein was consis-
tently expressed in normal breast tissue (Figure S5B). In
contrast, PTPN12 was undetectable in 37% of invasive breast
cancers (example images shown in Figure 4I and Figure S5C).
Strikingly, loss of PTPN12 expression occurred most frequently
in TNBC (60.4% of TNBCs exhibit no detectable PTPN12
protein) (Figure 4J). In contrast, HER2-amplified tumors only
rarely exhibited loss of PTPN12 expression (9.1% of HER2-
amplified tumors). The near-mutual exclusivity of HER2 amplifi-
cation and PTPN12 loss (p < 0.0001 by Fisher’s exact test)
suggests functional redundancy between these two events in
tumorigenesis, and is consistent with the model that PTPN12
and HER2/EGFR RTKs operate in the same genetic pathway.
Collectively, these results indicate that PTPN12 is frequently
inactivated by deletion, sequence variation, or loss of protein
expression, and PTPN12 loss of function may be a major deter-
minant in aggressive TNBC.
PTPN12 Is Posttranscriptionally Regulated by a REST-
miR-124 Network in Human Breast Cancer
Our observation that PTPN12 protein levels were frequently
undetectable in primary human breast cancers led to us to
examine the mechanism(s) by which PTPN12 expression is
lost. By examining other suppressors of HMEC transformation,
we observed that the tumor suppressor REST was also lost in
primary breast cancers (example images in Figure 5A), and the
expression of REST and PTPN12 was highly correlated (p <
0.0001; Figure 5B), suggesting that PTPN12 and REST may beFigure 4. PTPN12 Is Functionally Inactivated in Human TNBC via Multi
(A) PTPN12mutations occurmore frequently in human TNBC. Frequency ofmutat
breast cancers positive for ER and/or HER2.
(B) Schematic of PTPN12mutations in TNBCs. Red stars indicate altered amino ac
preceding histidine, H230, is conserved among all tyrosine phosphatases. The ph
(C) H230Y mutant PTPN12 fails to suppress transformation. TLM-HMECs expre
cDNAs. Cells were assessed for anchorage-independent growth.
(D) E690 and W699 PTPN12 mutants fail to suppress transformation. TLM-HM
cDNAs (as indicated) and assessed for anchorage-independent growth.
(E) The PTPN12-T573A SNP is a partial loss-of-function allele for suppressing trans
with lentiviral cDNAs encoding PTPN12-WT (threonine at residue 573), or PTPN
pendent growth.
(F) PTPN12-H230Y mutation disrupts proper acinar formation. MCF10A cells ex
mutant PTPN12 were analyzed for 3D acinar formation (day 15 after seeding).
(G) PTPN12-H230Y mutation disrupts proper acinar formation. Quantification of
(H) The PTPN12-T573A SNP allele disrupts acinar formation. MCF10A cells transd
573), or PTPN12-T573A (alanine at residue 573) as indicated were analyzed for 3
(I) Loss of PTPN12 expression occurs more frequently in human TNBC. Primary
PTPN12 expression. Representative panels exhibiting positive PTPN12 expressio
(right panel).
(J) Loss of PTPN12 expression occurs predominantly in TNBC. Primary human b
expression. The number of samples showing no detectable PTPN12 expressio
negative subtypes. Association between PTPN12 expression and breast cancer
Error bars represent standard error.coordinately regulated. REST is a transcription factor that
represses neuronal genes in non-neural tissues, and plays
a prominent tumor suppressor role in epithelial tissues (West-
brook et al., 2005), though the mechanism by which REST
suppresses tumorigenesis is poorly understood.
Based on the coordinate expression of REST and PTPN12 in
human breast cancers and their similar phenotypes, we tested
whether REST functions in a genetic pathway with PTPN12 by
regulating its expression. Consistent with this hypothesis, trans-
genic REST expression led to a substantial increase in endoge-
nous PTPN12 protein level in HCC70 (Figure 5C) and other TNBC
cell lines (data not shown). Based on the established role of
REST as a transcriptional repressor, we hypothesized that
REST positively regulates PTPN12 expression via an indirect
mechanism, perhaps by repressing an inhibitor of PTPN12
protein levels.
microRNAs are an emerging class of negative regulators, and
we observed that the PTPN12 30UTR has three evolutionarily
conserved binding sites for miR-124 (Figure 5D), a microRNA
suggested to play a role in neural development (Lim et al.,
2005). Importantly, miR-124 is transcriptionally repressed by
REST during organismal development, and REST inactivation
leads to elevated miR-124 expression in cells and tissues
(Conaco et al., 2006; Yoo et al., 2009). To determine whether
miR-124 regulates PTPN12 protein levels, we ectopically ex-
pressed miR-124-3 in HMECs. Transgenic miR-124 expression
led to a significant decrease in endogenous PTPN12 protein
levels (Figure 5E), suggesting that miR-124 may in part mediate
REST’s ability to inhibit PTPN12 protein expression.
The ability of miR-124 to inhibit the PTPN12 tumor suppressor
makes a strong prediction that miR-124 may function as an
oncogene. Indeed, ectopic expression of miR-124 led to robust
transformation of TLM-HMECs (Figure 5F), thus phenocopying
PTPN12 loss of function. Consistent with the role of miR-124
as a putative human oncogene, we observed frequent and focalple Mechanisms
ions observed in TNBCs (75 primary tumors and eight cell lines) and 202 primary
ids. The sequence surrounding the catalytic cysteine residue is expanded. The
osphatase domain (Phos Domain) and Proline rich regions (Pro1-5) are shown.
ssing the PTPN12-shRNA were engineered with the indicated dox-inducible
ECs expressing the PTPN12-shRNA were transduced with lentiviral PTPN12
formation. TLM-HMECswere transducedwith PTPN12-shRNA in combination
12-T573A (alanine at residue 573). Cells were measured for anchorage-inde-
pressing control or PTPN12 shRNA in combination with wild-type or H230Y
aberrant mammary acini from (F).
uced with lentiviral cDNAs encoding control, PTPN12-WT (threonine at residue
D acinar morphogenesis in vitro (day 15 after seeding).
human breast cancers (n = 185) were analyzed by immunohistochemistry for
n in HER2-amplified breast cancer (left panel) and lack of expression in TNBC
reast cancers (n = 185) were analyzed by immunohistochemistry for PTPN12
n (red area of bars) was quantified in HER2-positive, ER-positive, and triple-
subtypes was tested by Fisher’s exact test.
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Figure 5. PTPN12 Is Regulated by the REST Tumor Suppressor via miR-124
(A) Loss of REST expression in human breast cancer. Primary human breast cancers (n = 185) were analyzed by immunohistochemistry for REST expression.
Representative panels exhibiting negative and positive REST expression in invasive breast cancers.
(B) Loss of REST expression strongly correlates with loss of PTPN12 expression. Primary human breast cancers (n = 185) were analyzed by immunohisto-
chemistry for REST and PTPN12 expression. The level of PTPN12 (y axis) is plotted for tumors with absent, intermediate, or high REST levels (x axis). The median
and mean PTPN12 values for each group are represented by a solid red line and plus symbol, respectively. The boxes represent the 25th to 75th percentiles.
Association between PTPN12 and REST expression was tested by Fisher’s exact test. Error bars represent maximum and minimum observations within inner
fences.
(C) Ectopic REST expression increases PTPN12 protein levels in REST-deficient TNBC cells. HCC70 TNBC cells were transduced with control or REST cDNA,
cultured for 9 days, and analyzed for expression of REST and PTPN12 by western.
(D) Model for REST regulation of PTPN12 expression. REST regulates transcription of the neuronal microRNA miR-124. The PTPN12 30UTR contains three
conserved binding sites for miR-124. The sequences surrounding the three miR-124 binding sites are shown for human and five other vertebrate species.
(E) Ectopic miR-124 expression decreases PTPN12 protein levels in HMECs. HMECs were transduced with control or miR-124-containing plasmid, cultured for
7 days, and analyzed for PTPN12 expression by western.
(F) Ectopic miR-124 expression transforms TLM-HMECs. Cells from (E) were assessed for anchorage-independent proliferation.
Error bars represent standard error.
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amplifications of the miR-124-3 locus in human breast cancers
(Figures S6A and S6C). In a cohort of 243 breast cancers (Berou-
khim et al., 2010), 20.1%of tumors harbored amplifications in the
miR-124-3 locus, defining a MCR of amplification of 0.1 Mb
and encompassing only two NCBI-annotated genes (including
miR-124-3). miR-124-3 was similarly amplified (12.1%) in human
lung cancers (Figures S6B and S6C), suggesting that miR-124-3
and possibly other oncogenes exist on these amplicons. Collec-
tively, these data suggest that miR-124 may be a novel human
oncogene in epithelial cancers that transforms cells, in part, by
suppressing PTPN12 function.
PTPN12 Suppresses Growth and Metastasis
of PTPN12-Deficient Breast Cancer Cells
The observations described above implicate PTPN12 as a tumor
suppressor in TNBC. We next explored whether breast cancer
cells are functionally dependent on PTPN12 inactivation. We first
determined levels of PTPN12 in a panel of established breast
cancer cell lines. PTPN12 levels were similar in normal HMECs
and in HER2-amplified breast cancer cells (Figure 6A). In
contrast, several TNBC cell lines exhibited low PTPN12 protein
(Figure 6A), consistent with our observation that a significant
fraction of TNBC tumors have low or undetectable PTPN12
protein (Figure 4J). To determine whether TNBC cells with low
PTPN12 are sensitive to restoring PTPN12 levels, we transduced
TNBC cells with control- or PTPN12-expressing retrovirus (Fig-
ure S7). As shown in Figures 6B and 6C, ectopic expression of
PTPN12 decreased colony formation by TNBC cells, suggesting
that these cells are sensitive to reconstituting PTPN12 function.
The ability of cancer cells to grow in microenvironments with
altered or absent ECM is a hallmark of metastasis and is
mimicked, in part, by in vitro culture in the absence of ECM
support. Because our data indicate that PTPN12 is a potent
suppressor of anchorage-independent proliferation (Figure 1),
we tested the hypothesis that PTPN12 suppresses the meta-
static propensity of TNBC cells. Notably, in our analysis of
PTPN12 protein levels, we observed that the TNBC cell line
MDA-MB231 exhibited high PTPN12, whereas a highly tumori-
genic and metastatic subpopulation of MDA-MB231 (‘‘MDA-
MB231-LM2’’ cells; Minn et al. [2005]) exhibited 7-fold less
PTPN12 (Figure 6D). We hypothesized that suppression of
PTPN12 expression in this subpopulation of TNBC cells contrib-
utes to their aggressive tumorigenic and metastatic behavior.
To test this hypothesis we engineered MDA-MB231-LM2 cells
with a dox-inducible PTPN12 cDNA (Meerbrey et al., 2011)
(termed ‘‘LM2-IP’’ cells) and tested whether PTPN12 restoration
suppresses the tumorigenic and metastatic potential of LM2-IP
cells. Addition of dox to LM2-IP cells resulted in PTPN12 protein
levels comparable to parental MDA-MB231 cells (Figure 6D). To
assay their tumorigenic potential, LM2-IP or parental MDA-
MB231 cells were transplanted orthotopically into the mammary
gland in the presence or absence of dox. As shown in Figure 6E,
LM2-IP cells formed tumors rapidly. However, dox-induced
PTPN12 expression significantly reduced the tumorigenicity of
LM2-IP cells (Figure 6E; p < 0.0001) to the levels of parental
MDA-MB231 cells. Lungs collected from these animals revealed
significantly fewer metastases than dox-free animals (data not
shown). However, interpretation of these results was partiallyconfounded by the significantly larger primary tumor burden of
dox-free animals.
To circumvent the issue of tumor burden and directly assess
the effects of PTPN12 on lung metastatic colonization and
growth, we utilized an experimental model of metastasis (tail
vein injection) that measures colonization and expansion in the
lung. We injected LM2-IP cells into the tail vein, maintained
animals in the presence or absence of dox, and monitored
lung metastatic growth using luciferase luminescence-based
imaging (examples shown in Figure 6F, top panels). LM2-IP cells
injected into dox-free animals showed rapid expansion in the
lung (Figure 6F, bottom panel), consistent with the previously
reported behavior of MDA-MD231-LM2 cells (Minn et al.,
2005). In contrast, LM2-IP cells exhibited a significantly reduced
rate of expansion in dox-administered animals and showed no
increase in lung metastatic growth after day 21. To confirm the
luminescence-based readout, lungs were extracted from dox-
positive and dox-negative animals at the experimental endpoint
(day 35) and assessed for lung metastases. As shown in Fig-
ure 6G, dox-free animals showed significantly higher lung
metastatic burden relative to dox-administered animals. Taken
together, these data indicate that restoring PTPN12 function
constrains the tumorigenic and metastatic behavior of aggres-
sive TNBC cells.
PTPN12 Suppresses Proliferation and Tumorigenicity
of TNBCs by Inhibiting Multiple RTKs
Together, our observations strongly suggest that restoring
PTPN12 function impairs the tumorigenesis and proliferation of
PTPN12-deficient TNBCs, suggesting that these cancers are
dependent on the TK signaling constrained by PTPN12. Conse-
quently, we sought to identify TKs regulated by PTPN12 in
TNBC cells. Based on our observations that PTPN12 physically
associates with and inhibits EGFR and HER2 RTKs in HMECs,
we tested whether PTPN12 interacts with and regulates HER2
in PTPN12-deficient TNBC cells. BiFC analysis revealed a strong
interaction between PTPN12 andHER2 in TNBC cells (Figure 7A,
left panel). In addition, restoringPTPN12expression in these cells
decreased HER2 activity, as measured by HER2 tyrosine phos-
phorylation (Figure 7B). However, inhibition of HER family RTKs
(HER2 and EGFR) with a pharmacologic inhibitor did not signifi-
cantly affect the proliferation of these TNBC cells (Figure 7C),
indicating that inhibition of HER2 and EGFR activity does not
phenocopyPTPN12 restoration.Consequently,wehypothesized
that PTPN12 regulates other TKs that, alone or in combination
with HER2, are required for proliferation of TNBC cells.
To identify which additional TKs are regulated by PTPN12 in
TNBC cells, we tested several candidate TKs from our proteomic
analysis and previous reports (Cong et al., 2000; Markova et al.,
2003) for interaction with PTPN12 in TNBC cells via BiFC.
Notably, we observed a strong interaction between PTPN12
and PDGFR-b (Figure 7A, right panel), and ectopic PTPN12
expression reduced tyrosine phosphorylation of endogenous
PDGFR-b (Figure 7B), suggesting that PTPN12 regulates this
RTK in TNBCs. Notably, whereas inhibition of PDGFR-b alone
had only a modest effect on TNBC proliferation, combined inhi-
bition of HER2 family and PDGFR-b RTKs significantly impaired
TNBC proliferation (Figure 7C).Cell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc. 713
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Figure 6. PTPN12 Suppresses Growth and Metastasis of TNBC Cells
(A) PTPN12 expression is reduced in TNBC cell lines. PTPN12 protein levels were quantified by western in HMECs, TNBC cells, and HER2-amplified breast
cancer cells as indicated.
(B) Reconstituting PTPN12 expression suppresses proliferation in PTPN12-deficient breast cancer cells. TNBC cells expressing low endogenous PTPN12 were
transduced with equivalent multiplicity of infection (moi) of retrovirus encoding eGFP (control) or PTPN12 cDNAs and analyzed for macroscopic colony formation
in vitro.
(C) Reconstituting PTPN12 expression suppresses proliferation in PTPN12-deficient breast cancer cells. Quantification of colony number from cells in (B).
(D) PTPN12 expression is reduced in aggressive lung metastatic subpopulation of TNBC MDA-MB231 cells. PTPN12 protein expression was assessed in
MDA-MB231 breast cancer cells (231-parent) and in MDA-MB231-LM2 subpopulation that exhibits enhanced primary and lung metastatic tumor growth.
MDA-MB231-LM2 cells were engineered with an inducible PTPN12-cDNA (LM2-IP cells) that expresses similar PTPN12 levels as parental MDA-MB231 cells
upon addition of dox.
(E) Restoring PTPN12 expression suppresses primary tumor growth in aggressive TNBC cells. Cells from (D) were transplanted in themousemammary gland and
monitored for primary tumor growth in the presence or absence of dox (n = 12 for each group).
(F) Restoring PTPN12 expression suppresses lung metastatic growth in aggressive TNBC cells. Cells from (D) were tail vein injected and monitored for lung
metastatic growth (via luminescence detection) in the presence or absence of dox (n = 6 for each group). Representative +dox and dox images and quanti-
fication are shown in upper and lower panels, respectively.
(G) Restoring PTPN12 expression suppresses lung metastatic growth in aggressive TNBC cells. Cells from (D) were tail vein injected (as in F) in the presence or
absence of dox (n = 7) and analyzed for lung metastatic lesions via standard H&E.
Error bars represent standard error.
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Figure 7. PTPN12 Inhibits Proliferation and
Survival of TNBCs by Inhibiting Multiple
RTKs
(A) HER2 and PDGFR-b RTKs interact with
PTPN12 in TNBC cells. HCC1937 cells express-
ing PTPN12-N-YFP and individual RTK-C-YFP
cDNAs (as indicated) were analyzed for cellular
fluorescence using flow cytometry.
(B) Ectopic PTPN12 expression inhibits HER2 and
PDGFR-b RTK signaling in TNBC cells. HCC1937
cells engineered with control or PTPN12-cDNA
were assessed for PTPN12 expression and
levels of phosphorylated HER2 and PDGFR-b by
western.
(C) Combined HER family and PDGFR inhibitors
suppress proliferation of PTPN12-deficient TNBC
cells. HCC1937 cells were cultured ± HER2/
EGFR inhibitor lapatinib (1 mM) ± PDGFR inhibitor
sunitinib (5 mM) for 8 days. Cell numbers were
determined by DAPI cell counting.
(D and E) Combined HER family and PDGFR
inhibitors suppress tumorigenicity of PTPN12-
deficient TNBC cells. MDA-MB231-LM2 cells
were transplanted in the mouse mammary gland
and monitored for primary tumor growth in the
presence or absence of HER2/EGFR inhibitor
(lapatinib) and PDGFR inhibitor (sunitinib) as
indicated (n = 10 for each group). Tumor volumes
on day 26 postinjection are shown in (D). Tumor
growth curves are shown in (E).
(F) Combined HER family and PDGFR inhibitors
extend event-free survival of animals harboring
PTPN12-deficient TNBC tumors. Animals trans-
planted with MDA-MB231-LM2 cells (as above)
were treated with the indicated inhibitor and
monitored for tumor volume. Events are denoted
as animals with tumors greater than 1000 mm3.
Error bars represent standard error.To determine whether PTPN12-deficient TNBCs are combina-
torially dependent on the HER family and additional RTKs, such
as PDGFR-b in vivo, we tested the effects of the pharmacologic
inhibitors lapatinib and sunitinib alone or in combination on the
tumorigenicity of aggressive PTPN12-deficient TNBCs. Lapati-
nib is a dual inhibitor of HER2 and EGFR, and sunitinib is an
inhibitor of PDGFR-b and other TKs. MDA-MB231-LM2 cells
were transplanted orthotopically, and mice were treated for
40 days with the indicated agents. Both agents were well
tolerated by all animals at the administered doses (alone and
in combination). Treatment with sunitinib alone resulted in
a decrease in tumor growth rate (Figures 7D and 7E). Strikingly,
whereas lapatinib alone did not affect tumor growth, lapatinib
treatment significantly increased the efficacy of sunitinib in
reducing tumor growth rate and burden (p = 0.003; Figures 7D
and 7E). In addition, combination therapy resulted in a significant
extension in event-free animal survival (p = 0.002; Figure 7F).
These data suggest that PTPN12-deficient TNBC tumors may
be combinatorially dependent on HER2 family and other RTKs.Although our interaction and signaling studies suggest that
PDGFR-b is one of these additional RTKs, and this is supported
by the efficacyof sunitinib, given thebroad specificity of sunitinib,
it is possible that RTKs in addition to PDGFR-bmay be involved.
Thus, additional genetic and pharmacologic studies are neces-
sary to determine the precise identities of the relevant RTKs
driving tumorigenesis in tumors lacking PTPN12. Collectively,
these studies identify PTPN12 as a significant tumor suppressor
and illustrate a dependency onPTPN12-regulated TK signaling in
TNBC, suggesting that these tumorsmay be successfully treated
with the appropriate combination of TK inhibitors.
DISCUSSION
The Tyrosine Phosphatase PTPN12 Is a Tumor
Suppressor in Human Breast Cancer
In this study, we demonstrate that the tyrosine phosphatase
PTPN12 is a potent tumor suppressor in human breast cancer.
Loss of PTPN12 phosphatase activity leads to aberrant acinarCell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc. 715
morphogenesis and cellular transformation in mammary epithe-
lial cells. PTPN12 is frequently compromised in breast cancer by
deletion, inactivating sequence variants, or loss of expression.
Importantly, in breast cancer cells exhibiting PTPN12 deficiency,
restoring PTPN12 expression to levels observed in normal
mammary epithelial cells suppresses proliferation, tumorigen-
esis, and metastasis. Together, these observations strongly
support the conclusion that PTPN12 is a suppressor of human
breast cancer.
A Network Governing Cellular Transformation
and Tumor Suppression
Our study shows that PTPN12 functions in concert with a collec-
tion of other oncogenes and tumor suppressors in a serial inhib-
itory network culminating in the regulation of proto-oncogenic
RTKs. We previously discovered that the oncogenic F box
protein b-TRCP acts to negatively regulate the REST tumor
suppressor (Westbrook et al., 2008). Here, we find that REST
positively regulates PTPN12 levels, in part, by negatively regu-
lating miR-124 that represses PTPN12 protein levels. Ectopic
miR-124 expression can also transform HMECs, and miR-124
is focally and frequently amplified in epithelial cancers of the
breast and lung, and is likely to act as an oncogene in these
contexts. Thus, we have discovered an extensive network of
serial negative regulation with alternating oncogenes and
tumor suppressors consisting of b-TRCP, REST, miR-124, and
PTPN12, which inhibits proto-oncogenic RTKs such as EGFR-
HER2 to control cell proliferation, survival, and tumorigenesis.
The Role of PTPN12 and HER Family Receptors
in ‘‘HER2-Negative’’ Breast Cancer
Approximately 20% of all breast cancers exhibit amplification
and overexpression of HER2, and many of these malignancies
are sensitive to HER2 inhibitors (Di Cosimo and Baselga, 2010).
However, there is significant controversy as to whether HER2
and other HER family RTKs play a role in breast cancers that do
not exhibit amplification/overexpression of the HER2 locus
(termed ‘‘HER2-negative’’). Our data support a model in which
PTPN12 inactivation leads to HER2/EGFR hyperactivity and
cellular transformation in HER2-negative breast cancers. This is
supported by several observations. First, PTPN12 interacts
with the HER2 and EGFR receptors in HMECs, and loss of
PTPN12 function leads to hyperactivation of HER-receptor
signaling in these cells. Conversely, transgenic expression of
PTPN12 suppresses HER2 signaling in HMECs and PTPN12-
deficient breast cancer cells. Second, PTPN12 inactivation
leads to mammary epithelial cell transformation that is at least
partially dependent on HER2 and EGFR. Third, HER2 activity is
diminished in PTPN12-deficient breast cancers when PTPN12
expression is restored. Fourth, inhibitors of HER2 and EGFR,
when combined with other TK inhibitors, reduce proliferation
and tumorigenicity of HER2-negative breast cancers lacking
PTPN12. Finally, we observe frequent inactivation of PTPN12
specifically in HER2-negative breast cancers (96% of PTPN12-
deficient breast cancers were HER2 negative). This mutually
exclusive relationship is consistent with PTPN12 andHER2 func-
tioning in a common genetic pathway. Moreover, the frequent
inactivation of PTPN12 in HER2-negative cancers suggests that716 Cell 144, 703–718, March 4, 2011 ª2011 Elsevier Inc.a significant subset of HER2-negative tumors may harbor aber-
rant HER2/EGFR signaling. Notably, whereas inhibitors targeting
HER2 or EGFR individually have not been effective in HER2-
negative breast cancers, dual EGFR/HER2 inhibitors have not
been rigorously tested in HER2-negative cancers such as
TNBC. Further studies will be necessary to determine whether
dual EGFR/HER2 inhibitors in combination with other TK inhibi-
tors are effective in HER2-negative cancers and whether
PTPN12 represents a biomarker for sensitivity to such agents.A New Rationale for Combinatorially Targeting TK
Signaling in TNBC and Other Cancers
TKs have been shown to be critical pathogenetic drivers in some
cancers, and the identification of oncogenic mutations and
amplifications in TKs have provided important biomarkers for
selecting cancers that are dependent on TK signaling and
amenable to targeted therapies (Druker, 2004; Slamon et al.,
1989). In contrast, TNBC is a particularly aggressive subtype of
breast cancer for which no single, dominantly acting TK has
been shown to drive the disease. Our discovery that PTPN12 is
a tumor suppressor frequently inactivated in TNBC that acts as
a negative regulator of HER2/EGFR and other TKs, such as
PDGFR-b and ABL (Markova et al., 2003), raises the possibility
that inhibitors of these proto-oncogenic TKs may be therapeutic
in TNBCwhen used in the appropriate combination. In support of
this prediction, our data indicate that lapatinib combined with
another TK inhibitor (sunitinib) significantly reduces the prolifera-
tion and tumorigenicity of TNBCs. Given the prevalence of
PTPN12 inactivation in TNBC and the addiction of these cancers
to PTPN12 dysfunction, it will be important to define the full spec-
trum of TKs that PTPN12 regulates in TNBC and other cancers
in order to rationally combine agents targeting these kinases.
In summary, these studies establish an important role for tyro-
sine phosphatases in antagonizing tumorigenesis. Our observa-
tions raise the important prediction that many malignancies
considered to be non-TK driven because of the absence of
a dominant TK mutation may indeed be dependent on TK
signaling. It is likely that in different cell types, different PTPs
may play roles similar to PTPN12 in suppressing tumorigenesis,
possibly by antagonizing different combinations of TKs. These
studies provide a rationale for identifying and employing TK
inhibitors to treat cancers not previously thought to be driven
by TKs due to an absence of biomarkers for TK dependency.
As noted above for TNBC, it is likely that these tumors would
not be fully dependent on a single TK but, rather, a combination
of TKs within the cell. Thus, a combinatorial inhibitor approach
would be required to treat these cancers, most of which are
likely to be untreatable today. Our studies warrant a closer
examination of the status of tyrosine phosphorylation in what
has been previously considered non-TK driven disease and the
identification of TKs whose basal activity might combinatorially
contribute to cancers harboring defects in PTPs.EXPERIMENTAL PROCEDURES
Vectors
The shRNA library targeting human kinases and phosphatases (six shRNAs/
gene) was synthesized using published methods (Cleary et al., 2004) and
cloned into a MSCV-based retroviral vector. Individual GIPZ lentiviral shRNAs
were from the Hannon-Elledge shRNA collection (Open Biosystems). shRNAs
targeting the 30UTR region of PTPN12 were designed using the BiopredSI and
RNAi Codex algorithms. For inducible RNAi or overexpression experiments,
shRNAs or cDNAs were subcloned into a dox-inducible lentiviral expression
system (Meerbrey et al., 2011).Cell Culture
HMECs expressing hTERT and SV40 LT (TLM-HMECs) (Westbrook et al.,
2005) were cultured in mammary epithelial growth medium (MEGM, Lonza).
Lung metastatic MDA-MB231-LM2 cells (Minn et al., 2005) were cultured in
DMEM (GIBCO) supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin. HCC1954, HCC38, and HCC1937
cells were cultured in RPMI-1640 (ATCC) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. MCF10A
cells (from J. Brugge, Harvard Medical School) were grown as previously
described (Petersen et al., 1992). All cell lines were incubated at 37C
and 5% CO2. Stable cell lines expressing indicated shRNAs or cDNAs
were generated by retroviral/lentiviral infection in the presence of 8 mg/ml
polybrene, followed by selection with appropriate antibiotic-resistance
markers.Tumorigenicity and Experimental Metastasis Assays
Orthotopic tumorigenicity assays were performed as previously described
(Minn et al., 2005). In drug treatment experiments, animals were gavaged
with lapatinib (100 mg/kg) and/or sunitinib (40 mg/kg) once daily and moni-
tored for tumor growth. For event-free survival analysis, events were denoted
as animals with tumors greater than 1000 mm3. Comparison between groups
was performed using Wilcoxon analysis. For experimental metastasis assays,
NOD/SCID female mice (NCI) aged-matched between 5 and 7 weeks were
treated with PBS or dox at 2 mg/kg by intraperitoneal (IP) injection. The 2 3
105 cells were resuspended in 0.1 ml PBS and injected into the lateral tail
vein. Lung metastatic progression was monitored and quantified using nonin-
vasive bioluminescence as previously described (Minn et al., 2005). Linear
model analyses (F test) were performed to test the effect of PTPN12 induction
on tumorigenicity (tumor growth) or metastatic expansion (luminescence) in
both assays.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at doi:10.1016/
j.cell.2011.02.003.ACKNOWLEDGMENTS
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